Prostate Cell News Volume 5.08 | Mar 7 2014

Ablation of the Oncogenic Transcription Factor ERG by Deubiquitinase Inhibition in Prostate Cancer
Scientists showed that ubiquitin-specific peptidase 9, X-linked, a deubiquitinase enzyme, binds E-twenty-six related gene (ERG) in VCaP prostate cancer cells expressing TMPRSS2-ERG and deubiquitinates ERG in vitro. [Proc Natl Acad Sci USA] Abstract | Full Article | Press Release

TR4 Nuclear Receptor Functions as a Tumor Suppressor for Prostate Tumorigenesis via Modulation of DNA Damage/Repair System
Knocking down testicular nuclear receptor 4 (TR4) in human RWPE1 and mouse mPrE normal prostate cells promoted tumorigenesis under carcinogen challenge, suggesting TR4 may play a suppressor role in prostate cancer initiation. [Carcinogenesis] Abstract

Arachidonic Acid Induction of Rho-Mediated Transendothelial Migration in Prostate Cancer
Microscopic analysis and measurement of adhesion and invasion of prostate cancer cells through bone marrow endothelial cells was undertaken with arachidonic acid stimulation and/or simvastatin treatment. [Br J Cancer] Abstract

Exposure to Bisphenol A Correlates with Early-Onset Prostate Cancer and Promotes Centrosome Amplification and Anchorage-Independent Growth In Vitro
In vitro studies examined centrosomal abnormalities, microtubule nucleation, and anchorage-independent growth in four prostate cancer cell lines and two immortalized normal prostate epithelial cell lines. Exposure to low doses of bisphenol A increased the percentage of cells with centrosome amplification two- to eight-fold. [PLoS One] Full Article | Press Release

Comparative Genomic and Transcriptomic Analyses of LNCaP and C4-2B Prostate Cancer Cell Lines
Exome sequencing detected 2188 and 3840 mutations in LNCaP and C4-2B cells, respectively, of which 1784 were found in both cell lines. Surprisingly, the parental LNCaP cells have over 400 mutations that were not found in the C4-2B genome. [PLoS One] Full Article

GPNMB/OA Protein Increases the Invasiveness of Human Metastatic Prostate Cancer Cell Lines DU145 and PC3 through MMP-2 and MMP-9 Activity
Researchers investigated the role of non-metastatic glycoprotein melanoma protein B (GPNMB)/osteoactivin (OA) in the progression of human metastatic DU145 and PC3 prostate cancer cells. [Exp Cell Res] Abstract

Development and Screening of a Series of Antibody-Conjugated and Silica-Coated Iron Oxide Nanoparticles for Targeting the Prostate-Specific Membrane Antigen
Antibody and prostate-specific membrane antigen (PSMA)-specific targeting of the optimized nanoparticle was evaluated using an isogenic PSMA-positive and PSMA-negative cell line pair. [ChemMedChem] Abstract

Rsf-1 Overexpression in Human Prostate Cancer, Implication as a Prognostic Marker
Researchers analyzed the expression pattern of Rsf-1 in human prostate cancer tissues and found that Rsf-1 was overexpressed in 45% of prostate cancer specimens. In addition, small interfering RNA knockdown in DU145 cells with high endogenous Rsf-1 expression decrease cell proliferation, colony formation, and invasion. [Tumor Biol] Abstract

CLINICAL RESEARCH

Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)
This Phase III study evaluated the efficacy and safety of earlier treatment with zoledronic acid in men with castration-sensitive metastatic prostate cancer. [J Clin Oncol] Abstract

Quantification of Skeletal Metastases in Castrate Resistant Prostate Cancer Predicts Progression Free and Overall Survival
Scientists reported a simplified and effective method for substratification of M1 castrate resistant prostate cancer by correlating progression free and overall survival with simple numeric quantification of skeletal metastases. [BJU Int] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Saskatchewan Grants Access to ZYTIGA^® for Men with Metastatic Prostate Cancer Prior to Chemotherapy
The inclusion of ZYTIGA^® (abiraterone acetate) on the Saskatchewan Cancer Agency Drug Formulary makes it the fourth province, following British Columbia, Québec and Ontario, to fund ZYTIGA^® through a provincial drug benefit plan for the treatment of metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy. [Janssen Inc.] Download Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR^TM can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Training Fellow – Cancer Biology (Institute of Cancer Research)

Postdoctoral Fellow – Prostate Cancer (Mayo Clinic- Rochester)

Postdoctoral Fellow – Biomarker Discovery In Prostate Cancer (University of California, San Francisco)

Postdoctoral Position – Cancer Biology/Genomics (Weill Cornell Medical College)

Experienced Researcher – Detection of Prostate Cancer Biomarkers (Dublin City University)

Postdoctoral Fellow – Role of Mitochondria in Cancer Progression (Baylor College of Medicine)

Postdoctoral Position – Prostate Cancer (Roswell Park Cancer Institute)

Postgraduate Position – Chemokine Receptor Induced Cell Migration (University of East Anglia)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.